Regulus Therapeutics Inc’s filing revealed that its Director Collier Kathryn J acquired Company’s shares for reported $7280.0 on Jul 25 ’24. In the deal valued at $1.82 per share,4,000 shares were bought. As a result of this transaction, Collier Kathryn J now holds 6,740 shares worth roughly $8762.0.
Then, CALSADA CRISPINA sold 5,468 shares, generating $6,510 in total proceeds. Upon selling the shares at $1.19, the Chief Financial Officer now owns 5,782 shares.
Before that, Aker Christopher Ray sold 5,468 shares. Regulus Therapeutics Inc shares valued at $6,510 were divested by the Sr. VP & General Counsel at a price of $1.19 per share. As a result of the transaction, Aker Christopher Ray now holds 10,056 shares, worth roughly $13072.800000000001.
Oppenheimer initiated its Regulus Therapeutics Inc [RGLS] rating to an Outperform in a research note published on August 02, 2024; the price target was $7. A number of analysts have revised their coverage, including Leerink Partners’s analysts, who began to cover the stock in mid March with a ‘”an Outperform”‘ rating. B. Riley FBR Inc. began covering RGLS with “Neutral” recommendation on March 28, 2018. Leerink Partners started covering the stock on January 05, 2018. It rated RGLS as “an Outperform”.
Price Performance Review of RGLS
On Monday, Regulus Therapeutics Inc [NASDAQ:RGLS] saw its stock fall -7.80% to $1.30. Over the last five days, the stock has lost -19.25%. Regulus Therapeutics Inc shares have fallen nearly -17.72% since the year began. Nevertheless, the stocks have fallen -0.76% over the past one year. While a 52-week high of $3.79 was reached on 01/06/25, a 52-week low of $1.08 was recorded on 01/13/25. SMA at 50 days reached $1.5292, while 200 days put it at $1.8328.
Levels Of Support And Resistance For RGLS Stock
The 24-hour chart illustrates a support level at 1.2167, which if violated will result in even more drops to 1.1333. On the upside, there is a resistance level at 1.4367. A further resistance level may holdings at 1.5733. The Relative Strength Index (RSI) on the 14-day chart is 33.83, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.1221, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 91.89%. Stochastics %K at 17.61% indicates the stock is a buying.
How much short interest is there in Regulus Therapeutics Inc?
A steep rise in short interest was recorded in Regulus Therapeutics Inc stocks on 2024-12-31, growing by 0.29 million shares to a total of 1.7 million shares. Yahoo Finance data shows the prior-month short interest on 2024-11-29 was 1.4 million shares. There was a rise of 17.36%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on June 13, 2017 when Chardan Capital Markets resumed its ‘”a Buy”‘ rating for the stock and retained the price target to $2.50.
